What is Knome?
Knome operates at the intersection of advanced computational biology and clinical diagnostics, providing the essential infrastructure required to manage complex next-generation sequencing (NGS) workflows. Through its proprietary knoSYS platform, the organization offers a scalable informatics architecture designed to interpret vast datasets of human genomic information with precision. Furthermore, the knomeDISCOVERY service provides pharmaceutical entities and academic institutions with deep-dive analytical capabilities into human exomes and genomes. By streamlining the path from raw sequence data to actionable biological insights, Knome serves as a critical partner for organizations aiming to enhance the efficacy of pharmaceutical development and precision medicine initiatives.
How much funding has Knome raised?
Knome has raised a total of $23.8M across 3 funding rounds:
Private Equity
$5M
Debt
$5.8M
Private Equity
$13M
Private Equity (2010): $5M, investors not publicly disclosed
Debt (2012): $5.8M, investors not publicly disclosed
Private Equity (2014): $13M, investors not publicly disclosed
Key Investors in Knome
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Knome?
With this major enterprise-level funding, Knome is poised to transition into a phase of aggressive market expansion and technological refinement. The strategic allocation of these resources will likely focus on enhancing the knoSYS platform's interoperability with existing hospital information systems and expanding the reach of its knomeDISCOVERY service. As the demand for large-scale genomic interpretation continues to surge within the pharmaceutical industry, Knome's ability to provide efficient, scalable solutions will be a key determinant in its long-term growth trajectory. The company is expected to leverage this capital to solidify its market leadership, potentially through increased investment in R&D and the scaling of its operational infrastructure to meet the rigorous demands of global clinical research programs.
See full Knome company page
